SAN DIEGO—(BUSINESS WIRE)—June 8, 2006—ACADIA PharmaceuticalsInc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders, today announced thatit will present at Needham & Company's Fifth Annual Biotechnology andMedical Technology Conference on Thursday, June 15, 2006, at 10:00a.m. Eastern Time at The New York Palace Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible on thecompany's website, www.acadia-pharm.com, under the investors sectionand an archived recording will be available on the website throughJune 29, 2006.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovativetechnology to fuel drug discovery and clinical development of noveltreatments for central nervous system disorders. ACADIA currently hasfive Phase II-stage clinical programs as well as a portfolio ofpreclinical and discovery assets directed at large unmet medicalneeds, including schizophrenia, Parkinson's disease, sleep maintenanceinsomnia, and neuropathic pain. All of the drug candidates in ACADIA'sproduct pipeline emanate from discoveries made using its proprietarydrug discovery platform. ACADIA's corporate headquarters is located inSan Diego, California and it maintains research and developmentoperations in both San Diego and Malmo, Sweden.
CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen, Vice President and Chief FinancialOfficer
858-558-2871